Metraipolis › archive › dc_f0fc0631646e
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting… — Europe PMC PMID:40973846
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40973846
- DOI
- 10.1007/s00277-[numero omesso]-w
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T20:38:54.656Z
- SHA-256 of the archived text
5c23748cb6fc3a83809ed67a16170c80a692c0994208fc3031f1c452e9d60ec9- Stable URL of this page
https://metraipolis.com/documento/dc_f0fc0631646e
How to cite
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting… — Europe PMC PMID:40973846 — Europe PMC (en), https://europepmc.org/article/MED/40973846 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f0fc0631646e (Metraipolis archive dc_f0fc0631646e, sha256 5c23748cb6fc3a83809ed67a16170c80a692c0994208fc3031f1c452e9d60ec9)
BibTeX
@misc{dcf0fc0631646e,
title = {Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting… — Europe PMC PMID:40973846},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40973846},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f0fc0631646e; sha256 5c23748cb6fc3a83809ed67a16170c80a692c0994208fc3031f1c452e9d60ec9},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40973846. Agents can read the archived copy with the MCP tool read_document.